Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
INTS
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. (INTS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
C+
Factor Score
2.5
/ 5.0
Growth
C+
Factor Score
2.7
/ 5.0
Profitability
D-
Factor Score
0.9
/ 5.0
Momentum
C-
Factor Score
2.1
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.5
EV / EBITDA
N/A
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-18.0%
Price Return 12M
-68.8%
Catalyst Signal
0.00
Market Cap
$10.8M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-195.9%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | C+ (2.7) | D- (0.9) | C- (2.1) | C+ (2.6) | C (2.2) |
| 2026-11-05 | C+ (2.5) | C+ (2.6) | D- (0.9) | C- (1.9) | C+ (2.7) | C- (2.1) |
| 2026-10-29 | C+ (2.5) | C+ (2.5) | D- (0.9) | D+ (1.8) | C+ (2.7) | C- (2.1) |
| 2026-10-22 | C+ (2.5) | C+ (2.5) | D- (0.9) | D+ (1.7) | C+ (2.6) | C- (2.0) |
| 2026-10-15 | C+ (2.5) | C (2.5) | D- (0.9) | D+ (1.6) | C+ (2.6) | C- (2.0) |
Page
1
of
4